Better gene knockout in aneuploid cell lines

IMAGE

Credit: ©2012, Mary Ann Liebert, Inc., publishers

New Rochelle, NY, May 15, 2019-CRISPR/Cas9 technology enables convenient and effective genome editing in diploid cell lines based on the isolation and expansion of edited single-cell clones. However, this approach is ineffective for aneuploid cell lines, and a group has now reported an improved method for genome editing based on multiple rounds of modification. The article is published in Tissue Engineering, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. Click here to read the article for free on the Tissue Engineering website until June 15, 2019.

Maxim N. Karagyaur, MD, PhD, Lomonosov Moscow State University, Russia, and a team of colleagues present their research in an article titled “Optimization of CRISPR/Cas9 Technology to Knock Out Genes of Interest in Aneuploid Cell Lines”. The authors treated four different human and mouse aneuploid cell lines in pooled populations and knocked out a combined six different genes. Their newly developed protocol includes repeated rounds of genome editing and GFP-positive cell sorting. Both on-target and off-target editing was assessed by sequencing predicted sites, and the results showed that additional rounds did not increase the rate of off-target cleavage despite enhancing gene knockout efficacy.

“Dr. Karagyaur and colleagues from Russia describe a critical development in CRISPR/Cas9 technology to create functional cell models from aneuploid cell cultures,” says Tissue Engineering Co-Editor-in-Chief John P. Fisher, PhD, Fischell Family Distinguished Professor & Department Chair, and Director of the NIH Center for Engineering Complex Tissues at the University of Maryland. “Utilizing an innovative approach of repetitive cycles of CRISPR-/Cas9, the group showed that target protein expression could be suppressed, and therefore bypass clonal effects which are often observed in these complex systems.”

###

About the Journal

Tissue Engineering is an authoritative peer-reviewed journal published monthly online and in print in three parts: Part A, the flagship journal published 24 times per year; Part B: Reviews, published bimonthly, and Part C: Methods, published 12 times per year. Led by Co-Editors-in-Chief Antonios G. Mikos, PhD, Louis Calder Professor at Rice University, Houston, TX, and John P. Fisher, PhD, Fischell Family Distinguished Professor & Department Chair, and Director of the NIH Center for Engineering Complex Tissues at the University of Maryland, the Journal brings together scientific and medical experts in the fields of biomedical engineering, material science, molecular and cellular biology, and genetic engineering. Leadership of Tissue Engineering Parts B (Reviews) and Part C (Methods) is provided by Katja Schenke-Layland, PhD, Eberhard Karls University, Tübingen, Heungsoo Shin, PhD, Hanyang University; and John A. Jansen, DDS, PhD, Radboud University, and Xiumei Wang, PhD, Tsinghua University respectively. Tissue Engineering is the official journal of the Tissue Engineering & Regenerative Medicine International Society (TERMIS). Complete tables of content and a sample issue may be viewed on the Tissue Engineering website.

About the Publisher

Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Stem Cells and Development, Human Gene Therapy, and Advances in Wound Care. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.

Media Contact
Kathryn Ryan
kryan@liebertpub.com

Comments